CVS Health (NYSE:CVS) Stock Price Target Lowered at Leerink Partners

CVS Health (NYSE:CVS) had its price objective trimmed by Leerink Partners from $119.00 to $112.00 in a research note published on Monday, MarketBeat Ratings reports. The firm currently has an outperform rating on the pharmacy operator’s stock.

CVS has been the topic of several other research reports. Wells Fargo & Company raised their price objective on CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a report on Monday, July 13th. BMO Capital Markets set a $112.00 target price on CVS Health in a report on Wednesday, September 9th. Robert W. Baird set a $107.00 target price on CVS Health in a research report on Thursday, August 6th. Weiss Ratings downgraded CVS Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday. Finally, UBS Group reissued a “buy” rating on shares of CVS Health in a research note on Tuesday, September 22nd. Twenty investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and an average price target of $107.80.

CVS Health Stock Performance

Shares of CVS Health stock opened at $87.93 on Monday. CVS Health has a fifty-two week low of $69.51 and a fifty-two week high of $110.68. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market capitalization of $112.46 billion, a P/E ratio of 23.26, a P/E/G ratio of 0.80 and a beta of 0.60. The company’s 50 day moving average price is $92.39 and its two-hundred day moving average price is $92.63.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. The firm had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company’s revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, equities analysts forecast that CVS Health will post 8.02 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be issued a $0.6650 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Thursday, October 22nd. CVS Health’s dividend payout ratio is presently 70.37%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CVS. Kilter Group LLC acquired a new position in CVS Health during the second quarter worth $27,000. Beaird Harris Wealth Management LLC lifted its stake in shares of CVS Health by 201.0% in the second quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock valued at $30,000 after buying an additional 195 shares in the last quarter. J.Safra Asset Management Corp bought a new position in shares of CVS Health in the second quarter valued at $30,000. Timbuktu Capital Management LLC acquired a new position in shares of CVS Health during the second quarter valued at about $31,000. Finally, Dunhill Financial LLC acquired a new position in shares of CVS Health during the second quarter valued at about $32,000. 80.66% of the stock is owned by institutional investors.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analyst sentiment remains supportive. Wall Street’s average brokerage recommendation is favorable, and Wall Street Zen upgraded CVS to “Strong Buy.” Leerink Partners also maintained an “Outperform” rating and its revised $112 price target implies substantial upside from recent trading levels, despite the reduction from $119. CVS Health Price Target Cut by Leerink Partners Wall Street Zen Upgrades CVS Health
• Positive Sentiment: Long-term distribution support improves business visibility. McKesson reached an agreement in principle to extend its pharmaceutical distribution partnership with CVS through June 2032, covering mail-order, specialty, retail pharmacy and distribution-center operations. The agreement reinforces a longstanding supplier relationship and may provide operational stability. McKesson Extends CVS Deal
• Positive Sentiment: Expansion and valuation are attracting investor interest. CVS is opening nearly 20 smaller neighborhood pharmacy locations in 2026. Its diversified insurance, pharmacy-benefit-management and retail businesses, along with a valuation viewed by some analysts as undemanding, support the potential recovery case. CVS Opens New Pharmacy Sites
• Neutral Sentiment: Valuation upside depends on earnings execution. CVS’s scale and multiple revenue streams may offer value, but investors need evidence that management can convert them into stronger profits as reimbursement pressure, rising medical costs and regulatory scrutiny persist. CVS Health Valuation Suggests Opportunity
• Negative Sentiment: Medicare Advantage and legal risks remain overhangs. Aetna’s Medicare Advantage star-rating setbacks could pressure reimbursement and profitability, while a legal probe adds uncertainty to the investment case. These concerns temper the bullish valuation and analyst views. Pharmacy Formats and Aetna Star Ratings at CVS

About CVS Health

CVS Health Corp. is an integrated health care company that provides pharmacy, insurance and health services primarily in the United States. Its operations are designed to connect consumers, health plans, health care providers and pharmacy services across multiple points of care.

The company’s major businesses include CVS Pharmacy retail locations, prescription fulfillment and consumer health products; CVS Caremark, a pharmacy benefit management business; and Aetna, which offers health insurance products and related services for employers, individuals, government programs and other organizations.